Clinical trialObservationalRecruiting
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
A Retrospective/Prospective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Observational
- Status
- Recruiting
- Study type
- Observational
- Start
- 2 January 2024
- Expected end
- 2 December 2026
- Enrollment
- 100 participants
- Sites
- 2
- Primary outcomes
- Retrospective prediction of pCR in resectable patients; Retrospective prediction of pCR in borderline resectable patients
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 23 July 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel. The information collected will be used to determine if there are any "biomarkers" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.